ArticleJournal of the advanced practitioner in oncology2022
Uterine Leiomyosarcoma.
Article in Journal of the advanced practitioner in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Liquid Biopsy in Uterine Leiomyosarcoma: Current Biomarkers, Emerging Technologies, and Future Perspectives.Current oncology reports · 2026Review
- Molecular carcinogenesis and genetic insights in leiomyosarcoma: involvement of PI3K/AKT/mTOR/MAPK/ERK pathway.American journal of cancer research · 2026Review
- A Case Report of Pancreatic Oligometastasis of Uterine Leiomyosarcoma.Case reports in oncological medicine · 2026Article
- STUMP Swiftly Followed by Large Adenomyoma in a Young Nulliparous Patient.Diagnostics (Basel, Switzerland) · 2025Article
- Long-term survival following serial pulmonary metastasectomies for uterine leiomyosarcoma: a case report.General thoracic and cardiovascular surgery cases · 2025Article
- MG132 induces cell type‑specific anticancer effects in uterine leiomyosarcoma cell lines.Molecular medicine reports · 2025Article
- Article
- Article
- Breast lump as the initial presentation of metastatic uterine leiomyosarcoma: a case report and comprehensive literature review.Croatian medical journal · 2024Review
- Leiomyogenic Tumor of the Spine: A Systematic Review.Cancers · 2024Review
- NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma.Turkish journal of medical sciences · 2024Article
- Article
- Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.Journal of cancer research and clinical oncology · 2023Article
- The Role of Pathogenesis Associated with the Tumor Microclimate in the Differential Diagnosis of Uterine Myocytic Tumors.Journal of clinical medicine · 2023Article
- The In Vitro Effects of Romina Strawberry Extract on 3D Uterine Leiomyosarcoma Cells.Nutrients · 2023Article
- Article
- Postoperative Survival and Clinical Outcomes for Uterine Leiomyosarcoma Spinal Bone Metastasis: A Case Series and Systematic Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Primary uterine osteosarcoma arising in a leiomyoma with rapid local recurrence: A case report.Gynecologic oncology reports · 2022Article
- Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leiomyosarcoma (LMS) is the most common soft tissue sarcoma in adults and can occur in any part of the body. Uterine leiomyosarcoma (uLMS) is the most common location for LMS, making up 2% to 5% of all uterine malignancies. It is an aggressive tumor that is challenging to treat because of its resistance to standard therapy. The majority of patients (60%) are diagnosed with early-stage disease. However, regardless of the stage, uLMS has a poor prognosis. Surgical resection is the cornerstone of treatment for patients with localized LMS independent of the site of origin. Adjuvant chemotherapy for early-stage disease remains controversial as multiple clinical trials have failed to demonstrate benefit on overall survival. Progress has been made in therapy for advanced and recurrent disease. This case study will highlight the current and emerging data regarding novel therapies for women with uLMS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.